Johnson & Johnson (J&J) has settled with Teva and Alvotech over the biosimilar to its most lucrative asset, Stelara. The deal allows AVT04 to enter the US market no later than February 2025. This follows a May 2023 agreement with Amgen over ABP 654, which will hit markets no later than January 1, 2025. Stelara is a human IgG1k monoclonal antibody that targets the IL-12 and IL-23 cytokines. Its p..
Biogen, a biotechnology company, has made changes to its board of directors ahead of its annual shareholder meeting. Three current directors will not stand for re-election and will be replaced by Susan Langer, who is currently serving as president of Souffle Therapeutics. The shake-up comes after board chair Stelios Papadopoulos announced he was stepping down from his post and will be succeeded ..
Struggling biotech company Turnstone Biologics has filed for an $86 million IPO on Nasdaq in hopes of raising funds to stay afloat, according to an SEC filing. The company had only $64 million in operating capital by March 2023 and suffered net losses of $30 million in 2022. Turnstone focuses on developing oncolytic viruses and tumor-infiltrating lymphocytes (TILs) to target cancer. Its partners..
Endo International has released PREVDUO, a pre-filled syringe that combines neostigmine methylsulfate and glycopyrrolate injection. This product is the first and only FDA-approved neostigmine-glycopyrrolate combination available in the US. The two ingredients have both been approved as single active ingredient drug products. By eliminating the need for two discrete syringe preparations and admin..
Clinical-stage biotech company Eccogene has raised CNY180m ($25m) in series B equity financing to support the development of its clinical-stage pipeline. The funding round was led by New Alliance Capital and Zhangjiang Healthcare Venture Capital, and included new investors Rockbleu Capital, YuFu Investment, Huajin Capital and Elikon Venture, as well as existing backers Delos Capital, Oriza Seed ..
InnoCare presented data on their drug pipeline at the European Hematology Association (EHA) 2023 Hybrid Congress. The company's orelabrutinib, an inhibitor of Bruton’s Tyrosine Kinase, was evaluated in a study to treat Primary Immune Thrombocytopenia. Results showed that both doses of orelabrutinib were safe for patients with ITP, and those who had previously responded to glucocorticoids or intr..
China Medical System Holdings Limited has announced that the first Diazepam Nasal Spray has been approved for marketing in China, making it the first drug approved in China for the treatment of seizure clusters. The product is indicated for the acute treatment of intermittent, stereotypic episodes of frequent seizure activity that are distinct from a patient's usual seizure pattern in patients w..
Precision oncology company Parthenon Therapeutics has had an article published in the Journal for ImmunoTherapy of Cancer (JITC) that identified key characteristics and issues relevant to the role immune exclusion plays in resistance to checkpoint therapy. The work was performed in collaboration with multiple US and international academic institutions. Parthenon recently initiated a Phase 1 tria..
Ferring Pharmaceuticals has been granted approval by the US Food and Drug Administration (FDA) for its ADSTILADRIN intravesical gene therapy manufacturing process. The drug is used to treat non-muscle invasive bladder cancer in adult patients with high-risk Bacillus Calmette-Guérin-unresponsive carcinoma in situ with or without papillary tumors. Ferring intends to make ADSTILADRIN available as p..
